Bristi Basu

Medical Oncologist

Research Group Home Page:: Jodrell Group

Work address:

Publications:: Circulating DNA as prognostic biomarker in patients with advanced hepatocellular carcinoma: a translational exploratory study from the SORAMIC trial.

E-pub date: 30 Sep 2019; Quantifying normal human brain metabolism using hyperpolarized [1-13C]pyruvate and magnetic resonance imaging.

E-pub date: 31 Dec 2018; Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high grade serous ovarian and squamous non-small cell lung cancer.

E-pub date: 30 Jun 2018; Hyperpolarized carbon-13 magnetic resonance spectroscopic imaging: a clinical tool for studying tumour metabolism.

E-pub date: 31 May 2018; A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma.

E-pub date: 20 Mar 2018; Drug development and clinical trial design in pancreatico-biliary malignancies.

E-pub date: 01 Jan 2018; Early Phase Clinical Trial Designs – State of Play and Adapting for the Future.

E-pub date: 31 Dec 2017; Symptoms and patient factors associated with diagnostic intervals for pancreatic cancer (SYMPTOM pancreatic study): a prospective cohort study.

E-pub date: 31 Dec 2016; Intensive cisplatin/oral etoposide for epithelial ovarian cancer: the Cambridge Gynae-Oncology Centre experience: too toxic for relapse?

E-pub date: 31 Mar 2016; Safety and Efficacy of Modified FOLFIRINOX for Advanced Pancreatic Adenocarcinoma: A UK Single-Centre Experience.

E-pub date: 31 Aug 2015; First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014.

E-pub date: 01 Aug 2015; Epirubicin, Cisplatin, and Capecitabine for Primary Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer: Results of a Retrospective, Single-Institution Study.

E-pub date: 31 Jul 2015; Progress in pancreatic cancer: moving beyond gemcitabine?

E-pub date: 31 Aug 2012; Creatinine clearance is associated with toxicity from molecularly targeted agents in phase I trials.

E-pub date: 01 Aug 2012; The role of angiogenesis inhibitors in the management of melanoma.

E-pub date: 01 Aug 2012; PARP inhibitors: mechanism of action and their potential role in the prevention and treatment of cancer.

E-pub date: 31 Jul 2012; Combining antiangiogenics to overcome resistance: rationale and clinical experience.

E-pub date: 30 Jun 2012; Targeting the DNA damage response in oncology: past, present and future perspectives.

E-pub date: 31 May 2012; Inhibition of MT1-MMP activity using functional antibody fragments selected against its hemopexin domain.

E-pub date: 01 Feb 2012; Targeting angiogenesis in melanoma: prospects for the future.

E-pub date: 01 Nov 2010; A phase 2 study of vatalanib in metastatic melanoma patients.

E-pub date: 31 Oct 2010; Targeting insulin-like growth factor signaling: rational combination strategies.

E-pub date: 01 Sep 2010; Perspectives in drug development for metastatic renal cell cancer.

E-pub date: 01 Jun 2010; Systemic therapy for neuroendocrine tumours of gastroenteropancreatic origin.

E-pub date: 31 Mar 2010; Angiogenesis in cutaneous malignant melanoma and potential therapeutic strategies.

E-pub date: 01 Nov 2009; Development of a Prognostic Model That Predicts Survival After Pancreaticoduodenectomy for Ampullary Cancer.

E-pub date: 01 Jan 1970; Show all Hide all

Tweets

Tweets by CRUK_CI

Cancer Research UK Cambridge Institute

Bristi Basu

Medical Oncologist

Circulating DNA as prognostic biomarker in patients with advanced hepatocellular carcinoma: a translational exploratory study from the SORAMIC trial.

Quantifying normal human brain metabolism using hyperpolarized [1-13C]pyruvate and magnetic resonance imaging.

Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high grade serous ovarian and squamous non-small cell lung cancer.

Hyperpolarized carbon-13 magnetic resonance spectroscopic imaging: a clinical tool for studying tumour metabolism.

A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma.

Drug development and clinical trial design in pancreatico-biliary malignancies.

Early Phase Clinical Trial Designs – State of Play and Adapting for the Future.

Symptoms and patient factors associated with diagnostic intervals for pancreatic cancer (SYMPTOM pancreatic study): a prospective cohort study.

Intensive cisplatin/oral etoposide for epithelial ovarian cancer: the Cambridge Gynae-Oncology Centre experience: too toxic for relapse?

Safety and Efficacy of Modified FOLFIRINOX for Advanced Pancreatic Adenocarcinoma: A UK Single-Centre Experience.

First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014.

Epirubicin, Cisplatin, and Capecitabine for Primary Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer: Results of a Retrospective, Single-Institution Study.

Progress in pancreatic cancer: moving beyond gemcitabine?

Creatinine clearance is associated with toxicity from molecularly targeted agents in phase I trials.

The role of angiogenesis inhibitors in the management of melanoma.

PARP inhibitors: mechanism of action and their potential role in the prevention and treatment of cancer.

Combining antiangiogenics to overcome resistance: rationale and clinical experience.

Targeting the DNA damage response in oncology: past, present and future perspectives.

Inhibition of MT1-MMP activity using functional antibody fragments selected against its hemopexin domain.

Targeting angiogenesis in melanoma: prospects for the future.

A phase 2 study of vatalanib in metastatic melanoma patients.

Targeting insulin-like growth factor signaling: rational combination strategies.

Perspectives in drug development for metastatic renal cell cancer.

Systemic therapy for neuroendocrine tumours of gastroenteropancreatic origin.

Angiogenesis in cutaneous malignant melanoma and potential therapeutic strategies.

Development of a Prognostic Model That Predicts Survival After Pancreaticoduodenectomy for Ampullary Cancer.

Tweets

CRUK CI staff links

Contact CRUK CI

Useful links

Study at Cambridge

About the University

Research at Cambridge

Bristi Basu

Medical Oncologist

Circulating DNA as prognostic biomarker in patients with advanced hepatocellular carcinoma: a translational exploratory study from the SORAMIC trial.

Quantifying normal human brain metabolism using hyperpolarized [1-13C]pyruvate and magnetic resonance imaging.

Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high grade serous ovarian and squamous non-small cell lung cancer.

Hyperpolarized carbon-13 magnetic resonance spectroscopic imaging: a clinical tool for studying tumour metabolism.

A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma.

Drug development and clinical trial design in pancreatico-biliary malignancies.

Early Phase Clinical Trial Designs – State of Play and Adapting for the Future.

Symptoms and patient factors associated with diagnostic intervals for pancreatic cancer (SYMPTOM pancreatic study): a prospective cohort study.

Intensive cisplatin/oral etoposide for epithelial ovarian cancer: the Cambridge Gynae-Oncology Centre experience: too toxic for relapse?

Safety and Efficacy of Modified FOLFIRINOX for Advanced Pancreatic Adenocarcinoma: A UK Single-Centre Experience.

First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014.

Epirubicin, Cisplatin, and Capecitabine for Primary Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer: Results of a Retrospective, Single-Institution Study.

Progress in pancreatic cancer: moving beyond gemcitabine?

Creatinine clearance is associated with toxicity from molecularly targeted agents in phase I trials.

The role of angiogenesis inhibitors in the management of melanoma.

PARP inhibitors: mechanism of action and their potential role in the prevention and treatment of cancer.

Combining antiangiogenics to overcome resistance: rationale and clinical experience.

Targeting the DNA damage response in oncology: past, present and future perspectives.

Inhibition of MT1-MMP activity using functional antibody fragments selected against its hemopexin domain.

Targeting angiogenesis in melanoma: prospects for the future.

A phase 2 study of vatalanib in metastatic melanoma patients.

Targeting insulin-like growth factor signaling: rational combination strategies.

Perspectives in drug development for metastatic renal cell cancer.

Systemic therapy for neuroendocrine tumours of gastroenteropancreatic origin.

Angiogenesis in cutaneous malignant melanoma and potential therapeutic strategies.

Development of a Prognostic Model That Predicts Survival After Pancreaticoduodenectomy for Ampullary Cancer.

Tweets

CRUK CI staff links

Contact CRUK CI

Useful links

Study at Cambridge

About the University

Research at Cambridge

This Site Uses Cookies